Get started

AI

Multiverse (AI) Road to MainnetOn FA side, Multiverse has a lot of solid backers (Samsung, XRP Capital, Huobi, Fenbushi Capital, Matric China, etc) that are known to help their investments succeed (pump), has staking launching this quarter, and mainnet launch in November. Expect it to revisit ATH area by mainnet launch, and look to exit around that time. It is currently a very low marketcap with only one exchange, and expect more exchanges to come soon, including obviously Huobi who is an investor. On TA side, breakout of the long-term triangle should provide a nice rally either way. Currently at long-term bottom support range, which has never broken since listing.
ALong
by csoreff
1
🟢 NEW POSITION $AI Target 86.22 for 46.43% $AI Target 86.22 for 46.43% Or double position at 31.54 With optional adds at 54.30, and 56.33 — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading. I finally added my YouTube Training Video to my profile tagline since I’m not allowed to on here. It’s a quick 15 minute training video on how to set up your chart and how to spot opportunities. So check here first but If you have questions just message me. If you understand options at all I’m trying to learn so shoot me some pointers…
NYSE:AILong
by SPYder_QQQueen_Trading
3
This is the most unrated SPACFirst off let's start off with the inevitable part, the world population is only increasing and as the world becomes modern it will only put more stress on and already broken supply chain. It's no secret that the pandemic put how unstable the global supply chain is on display. With all this demand we need a new way of growing food to support it, that is where Aerofarms steps in. Aerofarms is creating a ground breaking way to feed our constantly modernizing population and the best thing is these are not just ideas or dreams trying to sold in another SPAC deal. This is a real company with real revenue, about $4 million projected for 2021. Now I know that nothing crazy but with a TAM of 1.9 trillion and a substantial lead ahead of any competitors in the vertical farming field with patents, trade secrets, and partnerships. They have increased their presence in 200 stores by over 500% in Whole Foods, ShopRite, Baldor, amazonfresh, and freshdirect. Aerofarms meets the challenges of its sector head on with 59% more efficient lighting, automation integration, data science, product diversification, capital access. They are moving into berries and other crops with a seed library with over 500 entries along with their data science fueling their algos put in action by the bots. Their merger with Spring Valley (SV) will give them $347,000,000 which they will use to super charge their growth and cement their position as a leader in the industry. I have several sets of PTs 3 month, 6 month, 1 year, 3 year Month: Bullish Neutral Bearish Yolo 3 Month 15-18 15 13 20 6 month 18-19 16 15 25 1 year 20-23 18 16 28 3 year 25-27 20 17 35
SLong
by TradeBroInc
Bottom of the barrel trend. Only up from here. This company recently IPO'd (went public) and is in the robotic process automation industry which enhances companies’ workflows through automation. In essence, the company saves, time and resources of the employees by streamlining processes. Technically speaking, the company has been on a strong downtrend yet recently it has consolidated and has bounced off support various times. Additionally, the risk/reward is very compelling for this stock due to the fact that it has seen highs of the high 80s (+30%) range, yet the downside to low 60's or 10%. Furthermore, the stock has been getting purchased from the lucrative ARK fund. This can cause quite the stir amongst the fiance media community and further enhance its upside potential. More analysis on my profile.
NYSE:PATHLong
by howdydany
3
EVAX - Evaxion BiotechThe Biotech company Evaxion Biotech, EVAX, who develop drugs based on AI platforms, is poised to publish data from its phase 1/2a trials of EVX-01 and EVX-02 in the first half of 2021. According to Yahoo Finance there are currently two analysts with price targets for the share, $18 and $23. Evaxion is an AI-immunology platform company decoding the human immune system to discover and develop novel immunotherapies for cancer and infectious diseases. Evaxion have developed an AI-immunology core technology to deeply understand the biological processes relevant for engaging the immune system aiming to harness its powers through novel immunotherapies. Evaxions scalable AI-immunology core technology enables broad applicability across diseases with immunological components. With deep insights into the biological processes of the immune system, Evaxion bridges technology, engineering expertise and drug development know-how to bring novel immunotherapies to patients. Evaxion uses its proprietary AI-immunology platform to simulate the human immune system and generate predictive models to identify and develop unique immunotherapies and thereby revolutionizing the process of drug discovery and development. PIONEER PIONEER is Evaxions proprietary AI platform for the rapid discovery and design of patient-specific neoepitopes used to derive immuno-oncology therapies. It has been shown that neoepitopes, which arise from patient-specific tumor mutations, play a critical role in T-cell mediated antitumor immune response. EDEN EDEN is Evaxions second AI platform that rapidly identifies novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against bacteria. EDEN has been designed to rapidly identify those antigens that will trigger a robust protective immune response against almost any bacterial infectious disease. In addition, EDEN redesigns identified antigens to optimize their antigenic and structural properties as well prepare them for production, which allow us to move antigen candidates into the clinic far faster than traditional, vaccine discovery approaches. EDEN has been pre-clinically validated in seven different pathogens in mouse infection models, and Evaxion believes that their approach can be used to target almost any bacterial infection and rapidly enables the discovery and development of vaccine candidates. RAVEN RAVEN is Evaxions third proprietary AI platform that brings their unique, machine learning approach to vaccine design and development for viral diseases. RAVEN combines the essential AI tools from our PIONEER platform with structural bioinformatic tools from EDEN to arrive at a novel potent T- and B-cell vaccine design for emerging and mutating viral diseases. Pipeline Evaxion’ pipeline of immunotherapies addresses two of the biggest unmet medical needs worldwide – cancer and infectious diseases. Evaxion currently has four products in their pipeline. Two in pre-clinical and two in phase 2 trials. Evaxions lead candidates are EVX-01, for the treatment of metastatic and unresectable melanoma, non-small cell lung cancer, and bladder cancer; and EVX-02, for the adjuvant treatment of melanoma. EVX-01 and EVX-02 are both currently in Phase 1/2a trials, with data expected in the 1H21. Evaxion intends to expand their current pipeline both within cancer and infectious diseases, and into other disease areas as we continue to explore new frontiers in AI-immunology. IPO Evaxion raised $30 million by offering 3 million ADSs at $10, the low end of the range of $10 to $12. The company offered 0.3 million more ADSs than anticipated. Evaxion was listed on the NASDAQ on 5. february 2021.
NASDAQ:EVAXLong
by stensgaard81
CloudMD $DOC.V - Months of selling and consolidation done?CloudMD has been under selling pressure for months now. Today it closed its Vision Pros Acquisition and is expected to close its largest acquisition - Oncidium this month as well. The company can boast a 125-130mil revenue run rate. Vision Pros adds 22 mil in rev and 10% EBITDA margins to the bottom line for CloudMD. I have a position in this company. It has not been an easy 3-4 months. The rest of the week will prove out if this was a one and done green day yesterday or if buyers are serious and ready to take control again. PT on DOC is $3.96. Was a "top pick" on Bloomberg MarketCall June 23rd. At some point the market is going to start respecting that revenue and positive EBITDA that the company is set to report for this full fiscal year. currently trading at 3x sales. This should definitely be on the watchlist now. Look to see Buyers control Price around the 2SD Cross as highlighted. DCA approach the play here. DOC.V is a long hold for myself. Hope the chart and thoughts help. Please do you own DD and follow your own trading rules. Cheers, Luke
DLong
by LeBelleChart
3
Buy ARKW $125 to $135! LT Play, 9:1 R:RHere is the weekly chart for ARKW, the ARK Next Gen Internet ETF counting from inception, ARKW has completed a massive wave 3 followed by a deep wave 4 correction which means it'll have an equally powerful wave 5. Taking the equal legs target or wave 1 results in a 5th wave that does not cross the ATH, which means a true wave 5 should replicate the entire length of wave 3. In simple English that means Cathy's baby is gonna have another massive 2020 like move over the next year or so. ARKW contains all the companies and technologies you want to be invested in over the next decade: Tesla = EV's/autonomous driving/energy storage & generation.....will these technologies be more widely adopted or less? Shopify = e-commerce/online store fronts/social media based sales....will these technologies be more widely adopted or less? Twitter = digital home of presidents, countries, corporations and revolutions...will these technologies be more widely adopted or less? Square = digital payments/wallets/crypto....will these technologies be more widely adopted or less? Teledoc = centralized digital healthcare platform.....will these technologies be more widely adopted or less? Greyscale = Bitcoin exposure/digital gold....will these technologies be more widely adopted or less? Roku = Streaming media w/ Large scale creators.....will these technologies be more widely adopted or less? Spotify = streaming media w/ small scale creators.....will these technologies be more widely adopted or less? Twilio = Communication as a Service (CaaS) platform.....will these technologies be more widely adopted or less? Coinbase = Most trusted and legit onramp for crypto....will these technologies be more widely adopted or less? Take a look at these companies, their technologies, and the type of service they offer, and ask yourself....will these be more in demand over the next decade or less? If you dont think these technologies, these platforms are the future then you haven't been paying attention. Now is the chance to get in on the FAANGS of the future. Imagine having invested in google or amazon in early 2000's. This is the last chance for a while (there will be one more i believe) to get in on this action. Dont worry about quarterly % increases and EBTIDA margins and blah blah blah....let cathy and the analysts are ARK worry about that. YOU should only focus on being a part of the trend that will define the future. If someone told you to invest in the internet in 1990, knowing everything you know now, would you do it? So buy ARKW between 125 and 135, and thank me in 2030.
AMEX:ARKWLong
by ir-rizzle
Big Winners For Monday 6/12/21 According To My AIThis is my top 10 estimates for the highs of the day on Monday (6/12/2021) according to my AI program and for those users that have been following my ai idea updates, I have improved the ai quite a bit to provide much more accurate results and I have implemented a scoring system that ranges from +30 to -30 and this is essentially the AI confidence that the estimate will be reached so +30 is the highest confidence and -30 is the lowest confidence. Symbol | Last Close | Estimated High | Est% | Score CRIS | 8.01 | 10.10 | 26.11 | 25 WISH | 10.00 | 12.07 | 20.68 | 0 VIXY | 25.23 | 30.27 | 19.99 | 0 CAN | 8.72 | 10.29 | 17.97 | 15 TAL | 29.23 | 34.30 | 17.36 | 25 PROG | 3.21 | 3.70 | 15.39 | 10 SPCE | 35.10 | 39.40 | 12.24 | -25 RUN | 44.96 | 50.39 | 12.08 | -20 ESTC | 136.67 | 153.05 | 11.98 | -20 CAKE | 56.08 | 61.73 | 10.07 | 0 I have made CRIS the chart since it is at the top of my list and the indicators because they are my favorites. I will update this idea with the actual highs of the day of course. This is an ongoing series for me so make sure to share your opinions, positive or negative. Thanks for following!
NASDAQ:CRISLong
by cheatcountry
4
IBM breaking 8 year downtrendIBM is beginning to break out on the weekly chart from a trend line that was acting as strong resistance for over 8 years. Recently the company has unveiled the world's first 2nm chip and announced previously that it will begin focusing on Cloud and AI which will serve the company well as those are two large secular growth stories. Go Long IBM. Trades at 9.79 EV/EBITDA ratio, well run company financially with a long growth path ahead of it. I expect IBM and INTC to be some of the main beneficiaries of the bill that just passed in the senate today that okayed $54 billion dollars for the Semiconductor Industry to focus production on American soil and improve research efforts. INTC and IBM have long been the American blue-chip players in the space and are currently collaborating in advanced semiconductor research. This is a timely partnership as INTC is building two new fabs in Arizona and IBM just released its 2nm chip but does not manufacture its own chips (ahem ahem INTC). Long-term Price Target: $250 Daily Chart w/ Golden Cross:
NYSE:IBMLong
by EBITDAtiger
5
Strong Buy Now: The best setup digital AI company on the CSEBoy, I scan companies for a living and although this ones balance sheet (as I write this) may not be the best pick for VALUE today, it is certainly setup well for an earnings surprise going into Q2. The CEO has said they have realized over $1.5M USD of top line revenue with an entire MONTH left in the quarter. Not to mention - he even said he fully expects to see $15M annually in the near to medium term. They closed HUGE contracts - one of which is for 50k retail locations and even have partnered with Intel; their own app RADAR is on Intel's DOMAIN . That is huge material news that's stayed under the radar on the *little volume* CSE. This is my number 1 pick right now; this one will turn a lot of heads super quick. Also the chart is setup nicely for a long. Trade it, hold it, long term hold it whatever you chose to do just BUY it.
CSE:VSBYLong
by GK-Trades